crenezumab
Crenezumab is a fully humanized monoclonal antibody against human 1-40 and 1-42 beta amyloid, which is being investigated as a treatment of Alzheimer's disease. Crenezumab is highly homologous to solanezumab, another monoclonal antibody targeting amyloid-β peptides. In June 2022, the US National Institutes of Health announced that the drug failed as a medication for early-onset Alzheimer's disease following the results of a decade-long clinical trial. — Wikipedia
Clinical trial activity
12 trials · 4 clinical orgs · 0 marketing orgs
Earliest trial started Aug 1, 2008 (NCT00736775)
Timeline
Indications
Mechanism of action
- Beta amyloid A4 proteinINHIBITOR
APP inhibitor
Binds all forms of misfolded Amyloid beta proteins to prevent Amyloid beta aggregation and promote the disaggregation of existing Amyloid beta aggregates including plaques.
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaCrenezumab ↗
- ChEMBLCHEMBL2109301 ↗
- ChEMBLCHEMBL1743004 ↗
Also known as
- crenezumab
- crenezumab
- crenezumab
- mabt5102a
- mabt5102a
- rg-7412
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03977584 | Phase 2 | Jun 10, 2019 | Genentech, Roche, University of Arizona |
| NCT03491150 | Phase 3 | Apr 11, 2018 | Roche |
| NCT03114657 | Phase 3 | Mar 29, 2017 | Roche |
| NCT02670083 | Phase 3 | Mar 22, 2016 | Roche |
| NCT02427243 | Phase 1 | Apr 1, 2015 | Genentech, Roche |
| NCT02353598 | Phase 1 | Feb 26, 2015 | Genentech, Roche |
| NCT01998841 | Phase 2 | Dec 31, 2013 | Genentech, National Institute on Aging (NIA), University of Arizona |
| NCT01723826 | Phase 2 | Dec 7, 2012 | Genentech |
| NCT01397578 | Phase 2 | Aug 1, 2011 | Genentech |
| NCT01343966 | Phase 2 | Apr 1, 2011 | Genentech |
| NCT00997919 | Phase 1 | Oct 1, 2009 | Genentech |
| NCT00736775 | Phase 1 | Aug 1, 2008 | Genentech |
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Genentech | For profit | 9 | 9 | 2 | 2008 |
| Roche | For profit | 6 | 3 | 3 | 2015 |
| University of Arizona | Academic/Hospital | 2 | 0 | 1 | 2013 |
| National Institute on Aging (NIA) | Government | 1 | 0 | 1 | 2013 |